Staging and mode of treatment
Reading File
Finding Sources
Finding Sources
Searching PubMed
"gastric cancer" AND "peritoneal metastasis" AND "chemotherapy"
Reading File
Reading File
Reading File
Reading File
I now have all the information needed for a thorough analysis. Here is the complete staging and treatment plan for this patient:
Staging and Mode of Treatment: Mr. Banda Srinivas, 51-year-old Male - Carcinoma Stomach
TNM Staging (AJCC/UICC 8th Edition)
Based on all clinical findings:
| Parameter | Finding | TNM |
|---|---|---|
| T (Primary Tumor) | Circumferential growth involving fundus and body; PET-CT shows significant perilesional fat stranding abutting left lobe of liver, left crus of diaphragm, body of pancreas | T4b (invasion of adjacent structures) |
| N (Nodes) | Multiple tiny enhancing rounded perilesional lymph nodes on PET-CT | N+ (at least N1-N2) |
| M (Metastasis) | Laparoscopy confirmed: peritoneal deposits on visceral peritoneum, multiple omental nodules, subdiaphragmatic nodularity | M1 (peritoneal seedlings = M1 per UICC staging) |
Final Stage: Stage IV (T4b, N+, M1)
The staging laparoscopy was the key step here. CT/PET-CT has very low sensitivity for peritoneal disease, and staging laparoscopy detects radiographically occult metastatic disease in 30-40% of patients - exactly what happened in this case. The laparoscopy revealed:
- Stomach distended with restricted mobility and thickened walls
- Multiple small deposits over the visceral peritoneum of the stomach
- Multiple omental nodules with greater omentum adherent to the stomach wall along the greater curvature
- Small nodularity over right and left subdiaphragmatic peritoneum
Per Bailey & Love's, "involvement of the liver or presence of peritoneal seedlings is staged as M1" - this patient has frank peritoneal carcinomatosis.
The histology (moderately to poorly differentiated adenocarcinoma with signet ring cell features) is particularly aggressive and the diffuse/poorly cohesive type is well-known for peritoneal spread.
Biopsy Histology Significance
- Moderately to poorly differentiated adenocarcinoma with focal signet ring cell features
- This is the Lauren diffuse type, which has the highest propensity for peritoneal dissemination
- Signet ring cell component is associated with worse prognosis and poorer response to standard chemotherapy
- PD-L1 testing and HER2/NEU testing should be obtained for treatment planning
Mode of Treatment
Surgery is NOT indicated. Staging laparoscopy confirmed unresectable disease (peritoneal carcinomatosis). Non-curative gastrectomy offers no survival benefit and carries high complication and mortality rates. The hospital correctly discharged him for chemotherapy.
1. Systemic Chemotherapy (Primary Treatment)
The standard first-line regimen for metastatic/unresectable gastric adenocarcinoma includes:
- FLOT (Docetaxel + Oxaliplatin + Leucovorin + 5-FU) - currently preferred
- FOLFOX (Oxaliplatin + Leucovorin + 5-FU)
- XELOX (Capecitabine + Oxaliplatin)
2. Targeted/Immunotherapy Add-ons (Based on Biomarker Testing)
| Biomarker | If Positive | Treatment Addition |
|---|---|---|
| HER2/NEU overexpression | ~15-20% of gastric cancers | Add Trastuzumab (ToGA regimen) |
| PD-L1 CPS ≥ 5 | Common in diffuse type | Add Nivolumab or Pembrolizumab |
| MSI-High / dMMR | Less common | Pembrolizumab monotherapy or combination |
A 2026 systematic review (PMID: 42092825) confirms immunotherapy + chemotherapy as first-line for HER2-negative advanced gastric cancer improves outcomes when stratified by PD-L1 expression.
3. Consider CRS + HIPEC (Selected Cases Only)
For patients with limited peritoneal disease who respond well to systemic chemotherapy, the emerging evidence supports:
- Neoadjuvant Chemotherapy (NACT) with FLOT followed by Cytoreductive Surgery (CRS) + Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Survival benefit: 17 months vs. 6 months (NACT-FLOT + CRS/HIPEC vs. chemotherapy alone)
- Ideal candidate criteria: age < 70, good PS, PCI < 10, small nodules, no liver/extraperitoneal mets, good response to NACT
This patient (51 years, ECOG 1, no liver mets confirmed, no free fluid) may be a candidate for CRS + HIPEC reassessment after 3-4 cycles of NACT if he demonstrates a good response.
Summary
| Aspect | Status |
|---|---|
| Stage | Stage IV (T4b N+ M1) - Peritoneal carcinomatosis confirmed |
| Resectability | Unresectable at present |
| Primary treatment | Systemic chemotherapy (FLOT/FOLFOX preferred) |
| Biomarker testing needed | HER2, PD-L1, MSI status |
| Re-evaluation | After 3-4 cycles: restage with CT/PET, consider CRS + HIPEC if good response and low PCI |
| Palliation | Full liquid diet, nutritional support, glycemic control (Diabetes Mellitus) |
| Prognosis | 5-year survival approaches 0% without treatment; median survival ~6-17 months with systemic/combined therapy |
The hospital's plan - discharge for chemotherapy with follow-up in Surgical Oncology OPD - is entirely appropriate for this Stage IV disease.
- Fischer's Mastery of Surgery, 8th ed., pp. 2955-2956
- Bailey and Love's Short Practice of Surgery, 28th ed., p. 67 (Table 67.6)
- Current Surgical Therapy, 14th ed., pp. 313-314
This is a shared conversation. Sign in to Orris to start your own chat.